{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:47:16Z","timestamp":1779342436466,"version":"3.51.4"},"reference-count":36,"publisher":"Termedia Sp. z.o.o.","issue":"3","license":[{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"},{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"},{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cent Eur J Immunol"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Celiac disease (CD) is the most common autoimmune disease (AD) of the small intestine, affecting 1-2% of the population globally. It is characterized by the serological presence of autoantibodies (Abs), tissue transglutaminase antibody (tTGA), immunoglobulin (Ig) A, and IgG. Production of antibodies against SARS-CoV-2 after infection with the virus or vaccination is not well understood, especially among CD patients. The goal of this study was to measure the IgG antibodies in Jordanian patients infected with or vaccinated against the SARS-CoV-2 virus with different types of vaccines (Pfizer- BioNTech BNT162b2, Sinopharm BBIBP-CorV or Oxford-AstraZeneca ChAdOx1-S) and compare them with the levels in non-celiac controls. IgG levels induced by different vaccines were also compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>The data for this cross-sectional study were obtained via a\u00a0survey, whereby respondents were identified through convenience sampling. The healthy controls were given Questionnaire A\u00a0while CD patients completed Questionnaire B. The blood samples from all participants were tested for the COVID-19 nucleocapsid protein (NP) IgG serum levels for participants previously infected with SARS-CoV-2, and spike (S) protein (S1\/S2) IgG serum levels for vaccine recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study involved 116 individuals, 60 (51.7%) of whom were CD patients. The NP IgG serum levels in the infected and S1\/S2 IgG levels in the vaccinated CD patients were significantly lower than the levels in controls (48.3 \u00b144.5 vs. 81.1 \u00b134.4 and 49 \u00b145.8 vs. 75.7 \u00b138.6, p = 0.002). Moreover, only the Pfizer vaccine induced significantly more IgG antibodies in controls compared to CD patients (88.8 \u00b129.1 vs. 58.3 \u00b145.4, p = 0.01). On the other hand, the IgG levels were significantly higher in CD patients who received the Pfizer relative to the AstraZeneca vaccine (58.3 \u00b145.5 vs. 13.0 \u00b123.6, p = 0.03). After adjusting for presence of CD, age, sex, body mass index (BMI), comorbidities, vaccine type, smoking, gluten adherence, and time since infection or vaccination, SARS-CoV-2 S1\/S2 IgG Abs and\/or NP IgG Abs positivity was significantly associated with CD absence and negatively with vaccine type (AstraZeneca) with the odds ratios (ORs) of 9.6 (95% CI = 1.5-59.2, p = 0.015) and 0.03 (95% CI = 0.004-0.244. p = 0.001), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We concluded that patients with CD had lower SARS-CoV-2 S1\/S2 IgG Abs and NP IgG Abs levels than controls, and CD patients who received the Pfizer vaccine had higher IgG levels than patients who received the AstraZeneca vaccine. We recommend that further research be conducted to address the dynamics of the antibody responses in CD patients regarding COVID-19 infection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5114\/ceji.2022.118649","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T04:09:43Z","timestamp":1660795783000},"page":"267-274","source":"Crossref","is-referenced-by-count":4,"title":["Humoral immune response to COVID-19 infection or vaccination among celiac disease patients"],"prefix":"10.5114","volume":"47","author":[{"given":"Eman","family":"Albatayneh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmeen","family":"Alabdallat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman","family":"Kreishan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanin","family":"Ayash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Abu-Lubad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3061","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"key":"ref-1538407","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/j.cgh.2020.04.040","article-title":"ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection","volume":"18","author":"Liu F","year":"2020","unstructured":"Liu F, Long X, Zhang B, et al. (2020): ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection. Clin Gastroenterol Hepatol 18: 2128-2130.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref-1538408","article-title":"WHO Coronavirus (COVID-19) Dashboard With Vaccination Data WHO","author":"WHO, WHO Coronavirus (COVID-19) Dashboard","unstructured":"WHO, WHO Coronavirus (COVID-19) Dashboard. WHO Coronavirus (COVID-19) Dashboard With Vaccination Data WHO."},{"key":"ref-1538409","article-title":"Ministry of Health, the official website of the Jordanian Ministry of Health","unstructured":"Ministry of Health, the official website of the Jordanian Ministry of Health. Coronavirus disease. 28\/12\/2021; available from: https:\/\/corona.moh.gov.jo\/en."},{"key":"ref-1538410","first-page":"386","article-title":"New-onset autoimmune phenomena post COVID-19 vaccination","volume":"165","author":"Chen Y","year":"2022","unstructured":"Chen Y, Xu Z, Wang P, et al. (2022): New-onset autoimmune phenomena post COVID-19 vaccination. Immunology 2022; 165: 386-401.","journal-title":"Immunology 2022"},{"key":"ref-1538411","doi-asserted-by":"crossref","first-page":"7433","DOI":"10.3748\/wjg.v27.i43.7433","article-title":"COVID-19 as a trigger of irritable bowel syndrome: A review of potential mechanisms","volume":"27","author":"Settanni CR","year":"2021","unstructured":"Settanni CR, Ianiro G, Ponziani FR, et al. (2021): COVID-19 as a trigger of irritable bowel syndrome: A review of potential mechanisms. World J Gastroenterol 27: 7433-7445.","journal-title":"World J Gastroenterol"},{"key":"ref-1538412","first-page":"1","article-title":"Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19","volume":"24","author":"Ni W","year":"2020","unstructured":"Ni W, Yang X, Yang D, et al. (2020): Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care 24: 1-10.","journal-title":"Crit Care"},{"key":"ref-1538413","doi-asserted-by":"crossref","first-page":"e9610","DOI":"10.15252\/msb.20209610","article-title":"The protein expression profile of ACE2 in human tissues","volume":"16","author":"Hikmet F","year":"2020","unstructured":"Hikmet F, M\u00e9at L, Edvinsson \u00c5, et al. (2020): The protein expression profile of ACE2 in human tissues. Mol Syst Biol 16: e9610.","journal-title":"Mol Syst Biol"},{"key":"ref-1538414","doi-asserted-by":"crossref","first-page":"100738","DOI":"10.1016\/j.nmni.2020.100738","article-title":"COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics","volume":"37","author":"Azer SA","year":"2020","unstructured":"Azer SA (2020): COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics. New Microbes New Infect 37: 100738.","journal-title":"New Microbes New Infect"},{"key":"ref-1538415","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1146\/annurev-immunol-040210-092915","article-title":"Integration of genetic and immunological insights into a model of celiac disease pathogenesis","volume":"29","author":"Abadie V","year":"2011","unstructured":"Abadie V, Sollid LM, Barreiro LB, et al. (2011): Integration of genetic and immunological insights into a model of celiac disease pathogenesis. Annu Rev Immunol 29: 493-525.","journal-title":"Annu Rev Immunol"},{"key":"ref-1538416","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrgastro.2015.136","article-title":"Coeliac disease and autoimmune disease-genetic overlap and screening","volume":"12","author":"Lundin KE","year":"2015","unstructured":"Lundin KE, Wijmenga C (2015): Coeliac disease and autoimmune disease-genetic overlap and screening. Nat Rev Gastroenterol Hepatol 12: 507-515.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref-1538417","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu N","year":"2020","unstructured":"Zhu N, Zhang D, Wang W, et al. (2020): A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382: 727-733.","journal-title":"N Engl J Med"},{"key":"ref-1538418","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1136\/gut.47.3.366","article-title":"IgG1 antiendomysium and IgG antitissue transglutaminase (anti-tTG) antibodies in coeliac patients with selective IgA deficiency","volume":"47","author":"Cataldo F","year":"2000","unstructured":"Cataldo F, Lio D, Marino A, et al. (2000): IgG1 antiendomysium and IgG antitissue transglutaminase (anti-tTG) antibodies in coeliac patients with selective IgA deficiency. Gut 47: 366-369.","journal-title":"Gut"},{"key":"ref-1538419","doi-asserted-by":"crossref","first-page":"0020319","DOI":"10.1177\/2050640613502788","article-title":"Serological testing for celiac disease in adults","volume":"1","author":"Schyum AC","year":"2013","unstructured":"Schyum AC, Rumessen JJ (2013): Serological testing for celiac disease in adults. United European Gastroenterol J 1: 0020319-325.","journal-title":"United European Gastroenterol J"},{"key":"ref-1538420","first-page":"415","article-title":"Celiac disease in Arabs","volume":"23","author":"Rawashdeh MO","year":"1996","unstructured":"Rawashdeh MO, Khalil B, Raweily E (1996): Celiac disease in Arabs. J Pediatr Gastroenterol Nutr 23: 415-418.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref-1538421","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1824-7288-36-16","article-title":"Serological screening for celiac disease in schoolchildren in Jordan. Is height and weight affected when seropositive?","volume":"36","author":"Nusier MK","year":"2010","unstructured":"Nusier MK, Brodtkorb HK, Rein SE, et al. (2010): Serological screening for celiac disease in schoolchildren in Jordan. Is height and weight affected when seropositive? Ital J Pediatr 36: 16.","journal-title":"Ital J Pediatr"},{"key":"ref-1538422","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41598-018-37747-5","article-title":"Development and evaluation of a multiplexed immunoassay for simultaneous detection of serum IgG antibodies to six human coronaviruses","volume":"9","author":"Trivedi SU","year":"2019","unstructured":"Trivedi SU, Miao C, Sanchez JE, et al. (2019): Development and evaluation of a multiplexed immunoassay for simultaneous detection of serum IgG antibodies to six human coronaviruses. Sci Rep 9: 1390.","journal-title":"Sci Rep"},{"key":"ref-1538423","first-page":"619","article-title":"Seroprevalence of COVID-19 and associated factors in a medical institution in Pakistan","volume":"16","author":"Naiyar I","year":"2021","unstructured":"Naiyar I, Anjum AF, Khalid AM, et al. (2021): Seroprevalence of COVID-19 and associated factors in a medical institution in Pakistan. J Taibah Univ Med Sci 16: 619-623.","journal-title":"J Taibah Univ Med Sci"},{"key":"ref-1538424","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","article-title":"Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2","volume":"182","author":"Wang H","year":"2020","unstructured":"Wang H, Zhang Y, Huang B, et al. (2020): Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell 182: 713-721.e9.","journal-title":"Cell"},{"key":"ref-1538425","doi-asserted-by":"crossref","first-page":"e0263468","DOI":"10.1371\/journal.pone.0263468","article-title":"Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection\u2013a comparative study from Novi Sad, Serbia","volume":"17","author":"Petrovi\u0107 V","year":"2022","unstructured":"Petrovi\u0107 V, Vukovi\u0107 V, Pati\u0107 A, et al. (2022): Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection\u2013a comparative study from Novi Sad, Serbia. PLoS One 17: e0263468.","journal-title":"PLoS One"},{"key":"ref-1538426","volume-title":"medRxiv","author":"Wei J","year":"2021","unstructured":"Wei J, Stoesser N, Matthews PC, et al. (2021): The impact of SARS-CoV-2 vaccines on antibody responses in the general population in the United Kingdom. medRxiv."},{"key":"ref-1538427","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1080\/21645515.2015.1069448","article-title":"Immune response to hepatitis B vaccine in patients with celiac disease: A systematic review and meta-analysis","volume":"11","author":"Opri R","year":"2015","unstructured":"Opri R, Veneri D, Mengoli C, et al. (2015): Immune response to hepatitis B vaccine in patients with celiac disease: A systematic review and meta-analysis. Hum Vaccin Immunother 11: 2800-2805.","journal-title":"Hum Vaccin Immunother"},{"key":"ref-1538428","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.vaccine.2010.11.060","article-title":"Long-term antibody persistence and immune memory to hepatitis B virus in adult celiac patients vaccinated as adolescents","volume":"29","author":"Zingone F","year":"2011","unstructured":"Zingone F, Morisco F, Zanetti A, et al. (2011): Long-term antibody persistence and immune memory to hepatitis B virus in adult celiac patients vaccinated as adolescents. Vaccine 29: 1005-1008.","journal-title":"Vaccine"},{"key":"ref-1538429","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1081-1206(10)63329-7","article-title":"Prevalence and diagnosis of celiac disease in IgA-deficient children","volume":"77","author":"Meini A","year":"1996","unstructured":"Meini A, Pillan NM, Villanacci V, et al. (1996): Prevalence and diagnosis of celiac disease in IgA-deficient children. Ann Allergy Asthma Immunol 77: 333-336.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref-1538430","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/00004836-199709000-00004","article-title":"Celiac sprue and immunodeficiency states: a 25-year review","volume":"25","author":"Heneghan MA","year":"1997","unstructured":"Heneghan MA, Stevens FM, Cryan EM, et al. (1997): Celiac sprue and immunodeficiency states: a 25-year review. J Clin Gastroenterol 25: 421-425.","journal-title":"J Clin Gastroenterol"},{"key":"ref-1538431","doi-asserted-by":"crossref","first-page":"e20094","DOI":"10.1097\/MD.0000000000020094","article-title":"The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials","volume":"99","author":"Wang H","year":"2020","unstructured":"Wang H, Xiao X, Xiao Q, et al. (2020): The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials. Medicine (Baltimore) 99: e20094.","journal-title":"Medicine (Baltimore)"},{"key":"ref-1538432","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1161\/01.RES.0000102865.60437.55","article-title":"Alteration of NMDA NR1 receptors within the paraventricular nucleus of hypothalamus in rats with heart failure","volume":"93","author":"Li YF","year":"2003","unstructured":"Li YF, Cornish KG, Patel KP (2003): Alteration of NMDA NR1 receptors within the paraventricular nucleus of hypothalamus in rats with heart failure. Circ Res 93: 990-997.","journal-title":"Circ Res"},{"key":"ref-1538433","doi-asserted-by":"crossref","first-page":"e00084","DOI":"10.1128\/CMR.00084-18","article-title":"Factors that influence the immune response to vaccination","volume":"32","author":"Zimmermann P","year":"2019","unstructured":"Zimmermann P, Curtis N (2019): Factors that influence the immune response to vaccination. Clin Microbiol Rev 32: e00084-18.","journal-title":"Clin Microbiol Rev"},{"key":"ref-1538434","first-page":"6","article-title":"The COVID-19 vaccination debate: CoV-2 in celiac disease: a pathogen or just along for the ride?","volume":"9","author":"Lerner A","year":"2021","unstructured":"Lerner A (2021): The COVID-19 vaccination debate: CoV-2 in celiac disease: a pathogen or just along for the ride? Int J Celiac Dis 9: 6-9.","journal-title":"Int J Celiac Dis"},{"key":"ref-1538435","doi-asserted-by":"crossref","first-page":"100120","DOI":"10.1016\/j.jtauto.2021.100120","article-title":"Celiac disease in the COVID-19 pandemic","volume":"4","author":"Samasca G","year":"2021","unstructured":"Samasca G, Lerner A (2021): Celiac disease in the COVID-19 pandemic. J Transl Autoimmun 4: 100120.","journal-title":"J Transl Autoimmun"},{"key":"ref-1538436","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cgh.2020.10.009","article-title":"The risk of contracting COVID-19 is not increased in patients with celiac disease","volume":"19","author":"Zhen J","year":"2021","unstructured":"Zhen J, Stefanolo JP, de la Paz Temprano M, et al. (2021): The risk of contracting COVID-19 is not increased in patients with celiac disease. Clin Gastroenterol Hepatol 19: 391-393.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref-1538437","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3748\/wjg.v27.i12.1213","article-title":"Risk perception and knowledge of COVID-19 in patients with celiac disease","volume":"27","author":"Zhen J","year":"2021","unstructured":"Zhen J, Stefanolo JP, de la Paz Temprano, et al. (2021): Risk perception and knowledge of COVID-19 in patients with celiac disease. World J Gastroenterol 27: 1213-1225.","journal-title":"World J Gastroenterol"},{"key":"ref-1538438","first-page":"92","article-title":"HLA-DRB1, DQA1 and DQB1 alleles and haplotypes frequencies in Iranian healthy adult responders and non-responders to recombinant hepatitis B vaccine","volume":"5","author":"Amirzargar AA","year":"2008","unstructured":"Amirzargar AA, Mohseni N, Shokrgozar MA, et al. (2008): HLA-DRB1, DQA1 and DQB1 alleles and haplotypes frequencies in Iranian healthy adult responders and non-responders to recombinant hepatitis B vaccine. Iran J Immunol 5: 92-99.","journal-title":"Iran J Immunol"},{"key":"ref-1538439","first-page":"308","article-title":"TH1 and TH2 responses are influenced by HLA antigens in healthy neonates vaccinated with recombinant hepatitis B vaccine","volume":"11","author":"Jafarzadeh A","year":"2012","unstructured":"Jafarzadeh A, Shokri F (2012): TH1 and TH2 responses are influenced by HLA antigens in healthy neonates vaccinated with recombinant hepatitis B vaccine. Iran J Allergy Asthma Immunol 11: 308-315.","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"ref-1538440","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1016\/j.cgh.2021.06.016","article-title":"An international reporting registry of patients with celiac disease and COVID-19: initial results from SECURE-CELIAC","volume":"19","author":"Uche-Anya E","year":"2021","unstructured":"Uche-Anya E, Husby S, Kaplan GG, et al. (2021): An international reporting registry of patients with celiac disease and COVID-19: initial results from SECURE-CELIAC. Clin Gastroenterol Hepatol 19: 2435-2437.e4.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref-1538441","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3899\/jrheum.200989","article-title":"Risk of adverse outcomes in hospitalized patients with autoimmune disease and COVID-19: a matched cohort study from New York City","volume":"48","author":"Faye AS","year":"2021","unstructured":"Faye AS, Lee KE, Laszkowska M, et al. (2021): Risk of adverse outcomes in hospitalized patients with autoimmune disease and COVID-19: a matched cohort study from New York City. J Rheumatol 48: 454-462.","journal-title":"J Rheumatol"},{"key":"ref-1538442","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.3390\/vaccines9121379","article-title":"Serum antibody response comparison and adverse reaction analysis in healthcare workers vaccinated with the BNT162b2 or ChAdOx1 COVID-19 vaccine","volume":"9","author":"Lim SH","year":"2021","unstructured":"Lim SH, Choi SH, Kim B, et al. (2021): Serum antibody response comparison and adverse reaction analysis in healthcare workers vaccinated with the BNT162b2 or ChAdOx1 COVID-19 vaccine. Vaccines (Basel) 9: 1379.","journal-title":"Vaccines (Basel)"}],"container-title":["Central European Journal of Immunology"],"original-title":[],"link":[{"URL":"https:\/\/ceji.termedia.pl\/pdf-152290-129642","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ceji.termedia.pl\/pdf-152290-129642","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T08:32:19Z","timestamp":1767947539000},"score":1,"resource":{"primary":{"URL":"https:\/\/ceji.termedia.pl\/Humoral-immune-response-to-COVID-19-infection-or-vaccination-among-celiac-disease,152290,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"alternative-id":["152290"],"URL":"https:\/\/doi.org\/10.5114\/ceji.2022.118649","relation":{},"ISSN":["1426-3912","1644-4124"],"issn-type":[{"value":"1426-3912","type":"print"},{"value":"1644-4124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,17]]}}}